Does Dr. DONNA KONLIAN have financial conflicts of interest?

Dr. DONNA KONLIAN (M.D., F.A.C.C.) has received a total of $5,760 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $5,760 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. DONNA KONLIAN?

According to CMS Open Payments data, Dr. DONNA KONLIAN received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($711), AMGEN ($613), and PFIZER ($479).

Does Dr. DONNA KONLIAN receive research grants or speaking fees?

Dr. DONNA KONLIAN has received $5,760 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. DONNA KONLIAN

M.D., F.A.C.C.Real-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: WAYNE, NJ 07470

NPI Number: 1144308115

LIFETIME INDUSTRY VALUE

$5,760

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. KONLIAN is a verified Internal Medicine, Cardiovascular Disease practitioner based in WAYNE, NJ.

Between 2021 and 2025, Dr. KONLIAN had an overall industry promotional and research financial footprint of $5,760 as recorded in the federal CMS Open Payments database.

$5,760 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. KONLIAN's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $711 (representing 12.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$711

12.3%

AMGEN

Rank 2

$613

10.6%

PFIZER

Rank 3

$479

8.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.